Edition:
United States

Latest Key Developments (Source: Significant Developments)

Dimerix Bioscience gets US patent allowance for kidney disease drug candidate
Thursday, 18 Feb 2016 05:45pm EST 

Dimerix Bioscience Ltd:Receipt of US patent allowance for chronic kidney disease.  Full Article

Sun Biomedical Ltd completes Dimerix Bioscience acquisition
Thursday, 2 Jul 2015 09:27pm EDT 

Sun Biomedical Ltd:Says completion of transaction to acquire Dimerix Bioscience Ltd as approved by shareholders at shareholder meeting held on June 30.  Full Article

Dimerix Bioscience Ltd shareholders sign sale agreements with Sun Biomedical Ltd
Monday, 15 Jun 2015 07:45pm EDT 

Sun Biomedical Ltd:Says that all shareholders of Dimerix Bioscience Ltd have signed share sale agreements for acquisition of Dimerix Bioscience by Sun Biomedical.Says execution of these agreements is a condition precedent for transaction.Says that it now expects to complete transaction following shareholder approval at general meeting on June 30, for acquisition of Dimerix and completion of tranche two capital raising via issue of 100 million shares at 1 cent.  Full Article

Sun Biomedical Ltd to acquire Dimerix Bioscience Ltd; announces $1.6 million capital raising
Tuesday, 12 May 2015 07:12pm EDT 

Sun Biomedical Ltd:Signs implementation agreement to acquire 100 pct. of Dimerix Bioscience Ltd, a public unlisted clinical stage drug discovery and development company, based in Melbourne.Says that in connection with acquisition, Sun Biomedical will undertake placement of up to 160,000,000 fully paid ordinary shares in the company to sophisticated and professional investor clients of Forrest Capital each at an issue price of $0.01 to raise up to $1.6 million (capital raising).Says that it will enter into acquisition agreement with each of Dimerix shareholders (to acquire 100 pct. ownership of Dimerix for total consideration of: 750,000,041 shares; 30,851,592 management options exercisable at A$0.020 on or before June 30, 2017;.75,000,040 Class B performance shares convertible into 75,000,040 shares; and 75,000,040 Class C performance shares convertible into 75,000,040 shares.  Full Article

More From Around the Web

No consensus analysis data available.